Digital single-operator cholangioscopy interobserver study using a new classification: the Mendoza Classification (with video) - 14/01/22
Abstract |
Background and Aims |
Digital single-operator cholangioscopy (DSOC) allows direct visualization of the biliary tree for evaluation of biliary strictures. Our objective was to assess the interobserver agreement (IOA) of DSOC interpretation for indeterminate biliary strictures using newly refined criteria.
Methods |
Fourteen endoscopists were asked to review an atlas of reference clips and images of 5 criteria derived from expert consensus. They then proceeded to score 50 deidentified DSOC video clips based on the visualization of tortuous and dilated vessels, irregular nodulations, raised intraductal lesions, irregular surface with or without ulcerations, and friability. The endoscopists then diagnosed the clips as neoplastic or non-neoplastic. Intraclass correlation (ICC) analysis was done to evaluate inter-rater agreement for both criteria sets and final diagnosis.
Results |
Clips of 41 malignant lesions and 9 benign lesions were scored. Three of 5 revised criteria had almost perfect agreement. ICC was almost perfect for presence of tortuous and dilated vessels (.86), raised intraductal lesions (.90), and presence of friability (.83); substantial agreement for presence of irregular nodulations (.71); and moderate agreement for presence of irregular surface with or without ulcerations (.44). The diagnostic ICC was almost perfect for neoplastic (.90) and non-neoplastic (.90) diagnoses. The overall diagnostic accuracy using the revised criteria was 77%, ranging from 64% to 88%.
Conclusions |
The IOA and accuracy rate of DSOC using the new Mendoza criteria shows a significant increase of 16% and 20% compared with previous criteria. The reference atlas helps with formal training and may improve diagnostic accuracy. (Clinical trial registration number: NCT02166099.)
Le texte complet de cet article est disponible en PDF.Abbreviations : CRM, DSOC, ICC, IOA
Plan
| DISCLOSURE: The following authors disclosed financial relationships: M. Kahaleh: Consultant for Boston Scientific, Interscope Med, and Abbvie; grant recipient from Boston Scientific, Conmed, Gore, Pinnacle, Merit Medical, Olympus Medical, and Ninepoint Medical; chief executive officer and founder of Innovative Digestive Health Education & Research Inc. M. Gaidhane: Consultant for Interscope Med; chief operations officer of Innovative Digestive Health Education & Research Inc. A. Tyberg: Consultant for Ninepoint Medical, EndoGastric Solutions, and Obalon Therapeutics. P. Kedia: Consultant for Boston Scientific, Apollo Endosurgery, Medtronic, and Olympus. I. Andalib: Consultant for ConMed. A. Sethi: Consultant for Boston Scientific, Olympus America, Medtronic, and Microtech. A. Slivka: Grant recipient from Boston Scientific and Olympus. P. A. Jamidar: Speaker for Boston Scientific. C. A. Robles-Medranda: Consultant for Pentax and Boston Scientific. I. Raijman: Speaker for Boston Scientific, ConMed, Medtronic, and GI Supplies; advisory board member for Microtech; co-owner of EndoRx. All other authors disclosed no financial relationships. |
|
| DIVERSITY, EQUITY, AND INCLUSION: One or more of the authors of this article self-identifies as an under-represented gender minority in science. One or more of the authors of this article self-identifies as a member of the LGBTQ+ community. One or more of the authors of this article self-identifies as an under-represented ethnic minority in science. |
Vol 95 - N° 2
P. 319-326 - février 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
